Your browser doesn't support javascript.
loading
Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice.
Brachs, Sebastian; Winkel, Angelika F; Tang, Hui; Birkenfeld, Andreas L; Brunner, Bodo; Jahn-Hofmann, Kerstin; Margerie, Daniel; Ruetten, Hartmut; Schmoll, Dieter; Spranger, Joachim.
Affiliation
  • Brachs S; Department of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Charité - University School of Medicine, Berlin, 10117, Germany; DZHK (German Center for Cardiovascular Research), Partner Site, Berlin, Germany. Electronic address: Sebastian.Brachs@charite.de.
  • Winkel AF; Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt am Main, 65926, Germany. Electronic address: Angelika.Winkel@sanofi.com.
  • Tang H; Department of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Charité - University School of Medicine, Berlin, 10117, Germany; DZHK (German Center for Cardiovascular Research), Partner Site, Berlin, Germany. Electronic address: Hui.Tang@charite.de.
  • Birkenfeld AL; Department of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Charité - University School of Medicine, Berlin, 10117, Germany; DZHK (German Center for Cardiovascular Research), Partner Site, Berlin, Germany; Section of Metabolic Vascular Medicine, Medical Clinic III and Pa
  • Brunner B; Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt am Main, 65926, Germany. Electronic address: Bodo.Brunner@sanofi.com.
  • Jahn-Hofmann K; Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt am Main, 65926, Germany. Electronic address: Kerstin.Jahn-Hofmann@sanofi.com.
  • Margerie D; Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt am Main, 65926, Germany. Electronic address: Daniel.Margerie@sanofi.com.
  • Ruetten H; Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt am Main, 65926, Germany. Electronic address: Hartmut.Ruetten@sanofi.com.
  • Schmoll D; Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt am Main, 65926, Germany. Electronic address: Dieter.Schmoll@sanofi.com.
  • Spranger J; Department of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Charité - University School of Medicine, Berlin, 10117, Germany; DZHK (German Center for Cardiovascular Research), Partner Site, Berlin, Germany. Electronic address: joachim.spranger@charite.de.
Mol Metab ; 5(11): 1072-1082, 2016 11.
Article in En | MEDLINE | ID: mdl-27818933
OBJECTIVE: Non-alcoholic fatty liver disease is a world-wide health concern and risk factor for cardio-metabolic diseases. Citrate uptake modifies intracellular hepatic energy metabolism and is controlled by the conserved sodium-dicarboxylate cotransporter solute carrier family 13 member 5 (SLC13A5, mammalian homolog of INDY: mINDY). In Drosophila melanogaster and Caenorhabditis elegans INDY reduction decreased whole-body lipid accumulation. Genetic deletion of Slc13a5 in mice protected from diet-induced adiposity and insulin resistance. We hypothesized that inducible hepatic mINDY inhibition should prevent the development of fatty liver and hepatic insulin resistance. METHODS: Adult C57BL/6J mice were fed a Western diet (60% kcal from fat, 21% kcal from carbohydrate) ad libitum. Knockdown of mINDY was induced by weekly injection of a chemically modified, liver-selective siRNA for 8 weeks. Mice were metabolically characterized and the effect of mINDY suppression on glucose tolerance as well as insulin sensitivity was assessed with an ipGTT and a hyperinsulinemic-euglycemic clamp. Hepatic lipid accumulation was determined by biochemical measurements and histochemistry. RESULTS: Within the 8 week intervention, hepatic mINDY expression was suppressed by a liver-selective siRNA by over 60%. mINDY knockdown improved hepatic insulin sensitivity (i.e. insulin-induced suppression of endogenous glucose production) of C57BL/6J mice in the hyperinsulinemic-euglycemic clamp. Moreover, the siRNA-mediated mINDY inhibition prevented neutral lipid storage and triglyceride accumulation in the liver, while we found no effect on body weight. CONCLUSIONS: We show that inducible mINDY inhibition improved hepatic insulin sensitivity and prevented diet-induced non-alcoholic fatty liver disease in adult C57BL6/J mice. These effects did not depend on changes of body weight or body composition.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Insulin Resistance / Dicarboxylic Acid Transporters / Symporters / RNA Interference / Lipid Metabolism / Non-alcoholic Fatty Liver Disease Type of study: Diagnostic_studies / Risk_factors_studies Limits: Animals Language: En Journal: Mol Metab Year: 2016 Type: Article

Full text: 1 Database: MEDLINE Main subject: Insulin Resistance / Dicarboxylic Acid Transporters / Symporters / RNA Interference / Lipid Metabolism / Non-alcoholic Fatty Liver Disease Type of study: Diagnostic_studies / Risk_factors_studies Limits: Animals Language: En Journal: Mol Metab Year: 2016 Type: Article